[e-farmacos] WHO Pharmaceutical Newsletter ultimo numero 2004

["Mariano y Martin" <e-farmacos@healthnet.org>]

Estimadas y estimados amigos,

En la web de la WHO-OMS ya esta el ultimo numero, num. 6, de 2004, del WHO
Pharmaceutical Newsletter:
http://www.who.int/medicines/library/pnewslet/6news2004.pdf

con el siguiente contenido:

TABLE OF CONTENTS

REGULATORY MATTERS
ACTRA-RX AND YILISHEN -- Presence of undeclared sildenafil
ADALIMUMAB -- Serious infections if used together with anakinra
ANTIDEPRESSANTS -- Label to warn of increased suicidality in children;
Patient Medication Guide to advise on risks and precautions to be taken 
ATORVASTATIN -- Interaction with grapefruit juice 
BLACK COHOSH COMBINATION #2; YELLOW DOCK COMBINATION #3- Presence of aristolochic acid
CELECOXIB -- Withdrawn in Turkey.
EPOETIN ALFA -- Label change to reflect thrombosis risk 
ETANERCEPT, INFLIXIMAB -- Reports of serious infections 
INFLIXIMAB -- Lymphoma warning added to label
ISOTRETINOIN -- Enhancement to risk management programme 
LEVOTHYROXINE SODIUM -- Dysphagia and risk of choking 
MIFEPRISTONE -- Important labelling changes proposed
PERGOLIDE MESYLATE -- Label change: risk of cardiac valvulopathy
REMINYL AND AMARYL -- Reports of medication errors 
VALDECOXIB -- Label updated to warn about skin reactions 

SAFETY OF MEDICINES
CHOLINESTERASE INHIBITORS -- Reports of cardiac arrhythmias 
CYCLO-OXYGENASE-2 INHIBITORS -- Plans to review all medicines in this class
ETHINYLESTRADIOL / CYPROTERONE -- Increased risk of thrombosis
HERBAL MEDICINES -- Cardiovascular ADRs reported to Health Canada
INFLUENZA VIRUS VACCINE -- Interactions with drugs
MEDROXYPROGESTERONE -- Effect on bone mineral density
PAMIDRONATE DISODIUM, ZOLEDRONIC ACID -- Spontaneous reports of osteonecrosis of the jaw
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) -- ADRAC reviews use in children and adolescents
TERBINAFINE -- Reports of blood dyscrasias
TRICYCLIC ANTIDEPRESSANTS -- Overdose risk

FEATURE
Twenty-seventh Annual Meeting of Representatives of the National Centres participating in the WHO Programme for International Drug Monitoring: Observations from Working Groups



Un abrazo,

Mariano Madurga
Agencia Espanhola de Medicamentos y Productos Sanitarios
www.agemed.es

y

Martin Canas
GAPURMED
La Plata
(Argentina)
macanas@netverk.com.ar